OmniAb, Inc. (OABI)
| Market Cap | 491.42M +95.4% |
| Revenue (ttm) | 38.46M +67.0% |
| Net Income | -44.27M |
| EPS | -0.35 |
| Shares Out | 145.39M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 554,415 |
| Open | 3.400 |
| Previous Close | 3.430 |
| Day's Range | 3.300 - 3.450 |
| 52-Week Range | 1.300 - 3.635 |
| Beta | 1.22 |
| Analysts | Strong Buy |
| Price Target | 7.33 (+116.86%) |
| Earnings Date | Aug 6, 2026 |
About OABI
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company’s technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners’ drug development efforts. Its OmniAb platform’s Biological Intelligence powers the immune systems of its proprietary and engineered transgenic anim... [Read more]
Financial Performance
In 2025, OmniAb's revenue was $18.67 million, a decrease of -29.27% compared to the previous year's $26.39 million. Losses were -$64.78 million, 4.43% more than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for OABI stock is "Strong Buy." The 12-month stock price target is $7.33, which is an increase of 116.86% from the latest price.
News
OmniAb announces collaboration and license agreement with Eli Lilly
OmniAb (OABI) announced a global collaboration and license agreement with Eli Lilly and Company (LLY) for a new ion channel program. The collaboration leverages OmniAb’s technology platform and expert...
OmniAb raises FY26 cash and equivalents view to $49M-$53M vs. $37M-$41M
OmniAb (OABI) raised its FY26 cash and cash equivalents financial guidance following recent technology licensing activity. “Recent business development and licensing activity has enabled us to again r...
OmniAb raises FY26 cash and equivalents view to $49M-$53M vs. $37M-$41M
OmniAb (OABI) raised its FY26 cash and cash equivalents financial guidance following recent technology licensing activity. “Recent business development and licensing activity has enabled us to again r...
OmniAb Raises 2026 Financial Guidance
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, toda...
OmniAb announces collaboration and license agreement with Eli Lilly
OmniAb (OABI) announced a global collaboration and license agreement with Eli Lilly and Company (LLY) for a new ion channel program. The collaboration leverages OmniAb’s technology platform and expert...
OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, toda...
OmniAb Slides: Corporate presentation
OmniAb has posted slides in relation to its latest quarterly earnings report, which was published on August 10, 2026.
OmniAb reports Q2 EPS (5c), consensus (13c)
Reports Q2 revenue $13.4M, consensus $4.69M. “We are pleased to report a strong quarter and to increase our revenue and cash outlook for 2026 based on continued momentum in our…
OmniAb Earnings Call Transcript: Q2 2026
Q2 2026 saw strong revenue growth and improved margins, driven by milestone achievements and expanding technology adoption. Guidance for 2026 was raised, with expectations for continued growth in milestones and royalties as clinical programs advance.
OmniAb Slides: Q2 2026
OmniAb has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
OmniAb Quarterly report: Q2 2026
OmniAb has published its Q2 2026 quarterly earnings report on August 6, 2026.
OmniAb Earnings release: Q2 2026
OmniAb released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
OmniAb Reports Second Quarter 2026 Financial Results and Business Highlights
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, toda...
Veraxa Biotech advances VXA-222 following milestone in OmniAb pact
Veraxa Biotech (VRXA) announced the advancement of bispecific ADC program VXA-222, following successful achievement of a key technical milestone in its alliance with OmniAb (OABI). The program is movi...
OmniAb to Report Second Quarter 2026 Financial Results on August 6
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, toda...
OmniAb names Nwachuku as Chief Operating Officer
OmniAb (OABI) announces that it has appointed Amechi Nwachuku to the newly-created position of Executive Vice President and Chief Operating Officer, effective today. Nwachuku will be primarily respons...
OmniAb Names Amechi Nwachuku Chief Operating Officer
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ:OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, announces that it has...
OmniAb reports Q1 EPS (6c), consensus (10c)
Reports Q1 revenue $14.4M, consensus $5.6M. “OmniAb (OABI) experienced strong momentum during the first quarter as multiple partnered programs advanced into later-stage clinical development, reinforci...
OmniAb raises FY26 revenue view to $28M-$33M, consensus $28.0M
OmniAb (OABI) revises 2026 financial guidance and now expects revenue to be in the range of $28 million to $33 million, versus $25 million to $30 million previously, and costs…
OmniAb Earnings Call Transcript: Q1 2026
Q1 2026 saw strong revenue growth driven by partner milestones and technology launches, leading to raised full-year guidance. Clinical pipeline progress and expanding AI-enabled platforms position the business for future royalty growth and sustained partner demand.
OmniAb Slides: Q1 2026
OmniAb has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
OmniAb Earnings release: Q1 2026
OmniAb released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
OmniAb Quarterly report: Q1 2026
OmniAb has published its Q1 2026 quarterly earnings report on May 7, 2026.
OmniAb Reports First Quarter 2026 Financial Results and Business Highlights
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2026, provided operating and partner program upda...